In a study with 82 melanoma patients treated with ipilimumab, Martens et al. found that an early increase in ALC 2 to 8 weeks after the start of treatments, followed by an increase in the relative percentages of CD4 and CD8 T cells (8-14 weeks after starting with treatment) correlated with improved survival [23]. The gene discussed is CD8A; the disease is melanoma.